Teva Pharma (TEVA) and Medincell Report Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749
Go back to Teva Pharma (TEVA) and Medincell Report Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749| TEVA PHARMACEUTICAL INDUSTRIES (NYSE: TEVA) | Delayed: 32.21 +0.73 (2.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.48 | 52 Week High | $66.55 | |||
| Open | $31.37 | 52 Week Low | $37.82 | |||
| Day High | $32.39 | P/E | N/A | |||
| Day Low | $31.28 | EPS | $0.00 | |||
| Volume | 5,272,895 | |||||
